ciprofloxacin has been researched along with pazufloxacin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brady, SF; Koirala, B; Peek, J | 1 |
| Fukuoka, Y; Ikeda, Y; Narita, H; Takahata, M; Todo, Y; Yamashiro, Y | 1 |
| Fukuda, Y; Kurose, S; Maehana, J; Minami, S; Mitsuyama, J; Narita, H; Todo, Y; Watanabe, Y; Yamada, H | 1 |
| Hayakawa, H; Kawamura, Y; Miyazaki, M; Nagasawa, M; Nakamura, S; Nojima, Y | 1 |
| Fukuda, H; Kawamura, Y | 1 |
| Fukuda, Y; Kamiyama, T; Mitsuyama, J; Mizunaga, S; Takahata, M | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
| Ito, K; Izumi, K; Mikamo, H; Tamaya, T; Tanaka, K; Watanabe, K | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Hiraoka, R; Nakazawa, K; Shinozaki, K; Suzuki, Y; Takeshita, K; Watabe, S; Yokoyama, Y | 1 |
| Dou, M; Gong, Y; Hao, J; Sun, C | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 2 |
1 trial(s) available for ciprofloxacin and pazufloxacin
| Article | Year |
|---|---|
[Effectiveness of switch therapy for peritonitis].
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Health Care Costs; Humans; Injections, Intravenous; Meropenem; Middle Aged; Naphthyridines; Ofloxacin; Oxazines; Peritonitis; Thienamycins | 2007 |
15 other study(ies) available for ciprofloxacin and pazufloxacin
| Article | Year |
|---|---|
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus | 2022 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Urinary Tract Infections | 1993 |
Characteristics of quinolone-induced small colony variants in Staphylococcus aureus.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; DNA Primers; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Oxazines; Polymerase Chain Reaction; Staphylococcus aureus; Structure-Activity Relationship | 1997 |
[Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Dermatitis, Phototoxic; Enoxacin; Female; Fluoroquinolones; Guinea Pigs; Nalidixic Acid; Ofloxacin; Oxazines; Quinolones; Rats; Rats, Sprague-Dawley; Ultraviolet Rays | 2002 |
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; beta-Alanine; Biphenyl Compounds; Cefazolin; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Convulsants; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Imipenem; Injections, Intravenous; Injections, Intraventricular; Male; Mice; Mice, Inbred ICR; Norfloxacin; Oxazines; Penicillin G; Quinolones; Seizures; Thienamycins | 2002 |
Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
Topics: Animals; Carbapenems; Ciprofloxacin; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Oxazines; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Simultaneous measurement of pazufloxacin, ciprofloxacin, and levofloxacin in human serum by high-performance liquid chromatography with fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Stability; Fluoroquinolones; Humans; Least-Squares Analysis; Levofloxacin; Ofloxacin; Oxazines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2010 |
Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Mutation; Oxazines | 2015 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Continuous Renal Replacement Therapy; Doripenem; Humans; Levofloxacin; Linezolid; Meropenem; Tandem Mass Spectrometry | 2023 |